You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Poly I:ploy C12U

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Post COVID-19 Condition, Long COVID Trial (Rintatolimod, Placebo / Normal Saline)

Not yet recruiting
  • Post COVID-19 Condition
  • Long COVID
  • (no location specified)
Oct 20, 2022

Chronic Fatigue Syndrome Trial in Incline Village, Charlotte (Poly I: Poly C12U (Rintatolimod))

Available
  • Chronic Fatigue Syndrome
  • Poly I: Poly C12U (Rintatolimod)
  • Incline Village, Nevada
  • +1 more
Apr 29, 2022

Pancreatic Cancer Trial (Rintatolimod)

Not yet recruiting
  • Pancreatic Cancer
  • (no location specified)
Aug 8, 2022

Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative Trial in Buffalo (procedure, drug, biological)

Active, not recruiting
  • Triple -Negative Breast Cancer
  • +4 more
  • Biopsy
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Aug 1, 2022

Non-ischemic Dilated Cardiomyopathy Trial in Spain (Control Strategy, Personalized precision ICD implantation Strategy based in

Not yet recruiting
  • Non-ischemic Dilated Cardiomyopathy
  • Control Strategy
  • Personalized precision ICD implantation Strategy based in genetic findings and CMR results
  • Santiago De Compostela, A Coruña, Spain
  • +26 more
Sep 20, 2023

Advanced Follicular Lymphoma:Translational Study From FIL_FOLL12

Not yet recruiting
  • Follicular Lymphoma
  • EZH2 mutations/CNAs by droplet digital PCR (ddPCR)
  • EZH2-derived gene expression signature by RNA-Seq
  • Alessandria, Italy
  • +25 more
Apr 4, 2023

Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL Trial in Spain (blinatumomab)

Terminated
  • Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
  • Badalona, Barcelona, Spain
  • +11 more
Jul 26, 2022

Evaluate the Safety and Useability of the ODOCOR II Intra-cardiac Lead Trial in Germany, Italy, Spain (ODOCOR II CCM LEADS)

Recruiting
  • Evaluate the Safety and Useability of the ODOCOR II Intra-cardiac Lead
  • ODOCOR II CCM LEADS
  • Heilbronn, Baden Wuerttemberg, Germany
  • +37 more
Nov 1, 2022

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid

Terminated
Has Results
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Mar 28, 2022

Philadelphia Positive, BCR-ABL Positive, Acute Lymphoblastic Leukemia Trial in Italy (Ponatinib)

Completed
  • Philadelphia Positive
  • +2 more
  • Alessandria, Italy
  • +41 more
Nov 18, 2021

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Philadelphia (OC-L/Montanide ISA 51 VG, Ampligen,

Terminated
Has Results
  • Ovarian Cancer
  • +2 more
  • OC-L/Montanide ISA 51 VG
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Oct 18, 2021

HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer Trial in Seattle (HER-2/neu peptide vaccine,

Completed
  • HER2-positive Breast Cancer
  • +7 more
  • HER-2/neu peptide vaccine
  • +2 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center/University of Washington
Feb 4, 2020

Untreated Philadelphia Positive Acute Lymphoblastic Leukemia, De Novo, Secondary Trial in Italy (Prephase PDN + CY, Cycle 1

Completed
  • Untreated Philadelphia Positive Acute Lymphoblastic Leukemia
  • +3 more
  • Prephase PDN + CY
  • +10 more
  • Alessandria, Italy
  • +60 more
Sep 6, 2021

Multiple Myeloma Trial in Worldwide (Selinexor, Elotuzumab, Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +67 more
Jul 26, 2022

Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) Trial in Worldwide (Dersimelagon, Placebo)

Not yet recruiting
  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)
  • Huntington Beach, California
  • +25 more
Nov 17, 2023

Real-life Current Standards of Care in Relapsed and/or

Completed
  • Multiple Myeloma
  • No intervention
  • Tucson, Arizona
  • +85 more
Dec 20, 2022

Prostate Cancer Trial in New York (Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM)

Completed
  • Prostate Cancer
  • Intratumoral (IT) Poly ICLC 0.5 mg
  • +3 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Sep 8, 2022

Primary Membranous Nephropathy Trial in Worldwide (Obinutuzumab, Tacrolimus, Methylprednisolone)

Recruiting
  • Primary Membranous Nephropathy
  • Mesa, Arizona
  • +75 more
Jan 10, 2023

Squamous NSCLC Trial in Italy (Nivolumab 10 MG/ML Intravenous Solution, Best Supportive Care)

Active, not recruiting
  • Squamous Non-small Cell Lung Cancer
  • Nivolumab 10 MG/ML Intravenous Solution
  • Best Supportive Care
  • Imola, Bologna, Italy
  • +30 more
Sep 30, 2022

Primary Mitochondrial Myopathy Trial in Worldwide (REN001, Placebo)

Recruiting
  • Primary Mitochondrial Myopathy
  • La Jolla, California
  • +42 more
Dec 7, 2022

Carcinoma, Renal Cell Trial in Worldwide (tivozanib HCl, Sorafenib)

Completed
Has Results
  • Carcinoma, Renal Cell
  • Phoenix, Arizona
  • +190 more
Jan 18, 2022

Malignant Tumor of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis Trial

Completed
Has Results
  • Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface
  • +2 more
  • DC vaccine
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 6, 2020

Breast Cancer Trial in Worldwide (gas chromatography / tandem mass spectometry)

Completed
Has Results
  • Breast Cancer
  • gas chromatography / tandem mass spectometry
  • Saint-Cloud, France
  • +23 more
Sep 27, 2021

Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, DLBCL

Active, not recruiting
Has Results
  • Adult Burkitt Lymphoma
  • +4 more
  • Chicago, Illinois
  • +4 more
Feb 17, 2022

Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 12, 2023